

EQA round: E21/24 - Hormones 2

Deadline: 2.2.2024

Setup: groups - M (measurement principle), R (manufacturer of kit); Slovakia; minimal size of the groups n = 5

RoM = robust average	AV = assigned value	D _{max} = acceptable difference
SD = standard deviation	CVPG = consensus of the participants' groups	LL = lower limit
CV = coefficient of variation	U _{AV} = expanded uncertainty of the assigned value (k = 2)	UL = upper limit
N _{tot} = total number of the results		N _{eva} = number of the results assessed
N _{out} = number of the results removed before calculation		N _{suc} = number of successful results
		S _{rel} = relative success

Test Sample Group	[unit]	RoM	SD	CV [%]	N _{tot}	N _{out}	Comparability					N _{eva}	N _{suc}	S _{rel} [%]
							AV	U _{AV}	D _{max}	LL	UL			
(393) C-peptide	[pmol/L]				10							7	7	100
Sample A		460	86	19	10							7	7	100
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		516	23	4,5	5	0	CVPG	513	15	20%	410	616	5	
Other					5	0							2	
							1x 4/1, 1x 4/12, 3x 4/179							
Sample B		406	66	16	10							7	7	100
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		456	19	4,1	5	0	CVPG	452	11	20%	361	543	5	
Other					5	0							2	
							1x 4/1, 1x 4/12, 3x 4/179							
(193) Ferritin	[µg/L]				16							15	14	93
Sample A		267	73	27	16							15	14	93
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		296	27	9,2	5	0	CVPG	315	3,5	24%	239	391	5	
Other					11	0							10	
							1x 4/1, 3x 4/12, 1x 4/162, 1x 4/179, 2x 6/58, 2x 6/60, 1x 6/178							
Sample B		157	37	23	16							15	14	93
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		173	39	23	5	0	CVPG	187	2,7	24%	142	232	5	
Other					11	0							10	
							1x 4/1, 3x 4/12, 1x 4/162, 1x 4/179, 2x 6/58, 2x 6/60, 1x 6/178							
(321) FSH	[U/L]				10							10	10	100
Sample A		39,8	3,8	9,5	10							10	10	100
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		38,5	1,4	3,8	5	0	CVPG	38	0,21	15%	32,3	43,7	5	
Other					5	0							5	
							1x 4/1, 4x 4/12							
Sample B		5,27	0,48	9,2	10							10	10	100
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		5,13	0,12	2,3	5	0	CVPG	5,08	0,029	15%	4,31	5,85	5	
Other					5	0							5	
							1x 4/1, 4x 4/12							
(328) hGH	[mU/L]				5							5	5	100
Sample A					5							5	5	100
Other					5	0							5	
							2x 4/12, 3x 4/29							
Sample B					5							5	5	100
Other					5	0							5	
							2x 4/12, 3x 4/29							
(329) IGF-1	[µg/L]				6							6	6	100
Sample A					6							6	6	100
Other					6	0							6	
							4x 4/29, 2x 4/60							
Sample B					6							6	6	100
Other					6	0							6	
							4x 4/29, 2x 4/60							
(392) IGF-BP3	[µg/L]				2							2	2	100
Sample A					2							2	2	100
Other					2	0							2	
							1x 4/29, 1x 4/60							
Sample B					2							2	2	100
Other					2	0							2	
							1x 4/29, 1x 4/60							
(325) Insulin	[mU/L]				7							7	7	100
Sample A					7							7	7	100
Other					7	0							7	
							1x 4/1, 1x 4/12, 3x 4/60, 2x 4/179							
Sample B					7							7	7	100
Other					7	0							7	
							1x 4/1, 1x 4/12, 3x 4/60, 2x 4/179							
(326) Folate	[nmol/L]				15							15	14	93
Sample A		46,3	5,8	12	15							15	15	100
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		42,9	3,7	8,6	8	0	CVPG	42	0,42	27%	30,6	53,4	8	
Other					7	0							7	
							1x 4/1, 3x 4/12, 3x 4/179							
Sample B		6,55	1,8	28	15							15	14	93
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		5,21	1,3	26	8	0	CVPG	5,26	0,12	27%	3,83	6,69	8	
Other					7	0							7	
							1x 4/1, 3x 4/12, 3x 4/179							

EQA round: E21/24 - Hormones 2

Deadline: 2.2.2024

Setup: groups - M (measurement principle), R (manufacturer of kit); Slovakia; minimal size of the groups n = 5

Test Sample Group	[unit]	RoM	SD	CV [%]	N _{tot}	N _{out}	Comparability					N _{eva}	N _{suc}	S _{rel} [%]
							AV	U _{AV}	D _{max}	LL	UL			
(320) LH	[U/L]				10							10	10	100
Sample A		63,5	11	17	10							10	10	100
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		73,1	1,6	2,2	5	0	CVPG	75,6	0,5	15%	64,2	87	5	
Other					5	0						5		
							1x 4/1, 4x 4/12							
Sample B		3,63	0,96	26	10							10	10	100
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		4,4	0,074	1,7	5	0	CVPG	4,63	0,038	15%	3,93	5,33	5	
Other					5	0						5		
							1x 4/1, 4x 4/12							
(405) Parathyrin intact (PTH)	[pmol/L]				13							13	12	92
Sample A		1,94	0,21	11	13							13	12	92
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		1,86	0,13	6,8	9	0	CVPG	1,79	0,017	23%	1,37	2,21	9	
Other					4	0						4		
							1x 4/1, 3x 4/12							
Sample B		9,38	1,2	12	13							13	12	92
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		8,92	0,36	4	9	0	CVPG	8,54	0,075	23%	6,57	10,6	9	
Other					4	1						4		
							1x 4/1, 3x 4/12							
(322) Prolactin	[mU/L]				10							10	8	80
Sample A					10							10	9	90
Other					10	0						10		
							1x 4/1, 3x 4/12, 4x 4/60, 2x 4/179							
Sample B					10							10	8	80
Other					10	0						10		
							1x 4/1, 3x 4/12, 4x 4/60, 2x 4/179							
(390) Renin	[ng/L]				3							2	1	50
Sample A					3							2	2	100
Other					3	0						2		
							1x 1/185, 2x 4/164							
Sample B					3							2	1	50
Other					3	0						2		
							1x 1/185, 2x 4/164							
(394) SHBG	[nmol/L]				8							8	8	100
Sample A		49,6	4,7	9,6	8							8	8	100
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		50,9	2,2	4,3	5	0	CVPG	49,2	0,37	20%	39,3	59,1	5	
Other					3	0						3		
							1x 4/1, 1x 4/12, 1x 4/179							
Sample B		32,2	1,6	5,1	8							8	8	100
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		32,2	0,22	0,69	5	0	CVPG	31,6	0,24	20%	25,2	38	5	
Other					3	0						3		
							1x 4/1, 1x 4/12, 1x 4/179							
(327) Vitamin B ₁₂	[pmol/L]				15							15	15	100
Sample A		543	88	16	15							15	15	100
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		597	78	13	8	0	CVPG	571	4,2	20%	456	686	8	
Other					7	0						7		
							1x 4/1, 3x 4/12, 3x 4/179							
Sample B		418	76	18	15							15	15	100
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		466	42	9,1	8	0	CVPG	437	3,6	20%	349	525	8	
Other					7	0						7		
							1x 4/1, 3x 4/12, 3x 4/179							
(319) Vitamin B ₁₂ (active)	[pmol/L]				5							0		
Sample A					5							0		
Other					5	0						0		
							1x 4/1, 4x 4/60							
Sample B					5							0		
Other					5	0						0		
							1x 4/1, 4x 4/60							